13 December 2017 - SpiroChem AG (“SpiroChem” or the “Company”), the Swiss fine chemicals company specialised in creating novel building blocks for use in drug discovery by pharma and biotech partners, today announced the completion of a successful fundraising to invest in further growth as demand for SpiroChem’s products and services continues to increase.
SpiroChem has continued to deliver a strong performance across all areas of the business. As a result, additional investment to scale the business is required to meet demand and further improve efficiency. The net proceeds from the funds raised will be used to accelerate sales and increase internal productivity by investing in state-of-the-art equipment.
The Company has completed this fundraising in parallel with its recent relocation to new, enlarged facilities in Basel. SpiroChem’s growing customer base reflects the Company’s premium service offering and specialism in crafting innovative solutions for problems encountered in challenging and complex projects in the medicinal chemistry field.
“This is an exciting time for SpiroChem as both the funds raised and relocation of the business provides the building blocks for us to significantly expand our operations as well as foster collaborations with existing and new customers and partners. We are delighted by the support our UK and Swiss investors have shown during this fundraise and their recognition of our strong progress and reputation as a partner of choice in the life sciences industry for outsourcing drug discovery research.
“As a result, we are making excellent progress and continue on our growth trajectory towards becoming a leading innovation and drug discovery partner to the pharmaceutical industry.”
SpiroChem AG is a Swiss Fine Chemical Company founded in 2011 as an ETH-Zürich spin-off (group of Prof. Erick Carreira). SpiroChem has established itself as a world-leader in the field of novel building blocks for drug discovery and the expert on bioisosteric switch strategies. The Company has a broad portfolio of clients across the biotech and pharmaceutical industry as well as world-leading fine chemical companies.
SpiroChem drives the new molecule and synthesis innovation process, leading the way to new classes of molecules with highly attractive cost/benefit profiles due their intrinsic properties: 1) improved physico-chemical and pharmaco-kinetic properties and 2) chemical novelty allowing the generation of new intellectual property. The beneficial properties of SpiroChem’s compounds mean that our clients can optimize their drug candidates faster, therefore accelerating their drug discovery programs.
With recognized excellence in drug design and proprietary process chemistry technologies, SpiroChem efforts have been recognized with several entrepreneurial awards. It is the recipient of two sizable Swiss government grants (KTI). The forward-thinking initiatives enable discovery and innovation within the framework of research collaborations with ETH-Zürich.
Explore a new world of possibilities for innovation and discovery.